iCAD, Inc. (NASDAQ:ICAD - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.49 and traded as high as $3.85. iCAD shares last traded at $3.79, with a volume of 439,254 shares.
Analyst Ratings Changes
ICAD has been the subject of several analyst reports. Laidlaw reaffirmed a "hold" rating on shares of iCAD in a report on Thursday, April 17th. Wall Street Zen started coverage on iCAD in a research report on Tuesday, May 20th. They issued a "sell" rating on the stock. BTIG Research cut shares of iCAD from a "buy" rating to a "neutral" rating in a research report on Wednesday, April 16th. Finally, Craig Hallum downgraded shares of iCAD from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th.
View Our Latest Report on iCAD
iCAD Stock Up 4.9%
The firm has a 50 day simple moving average of $2.99 and a two-hundred day simple moving average of $2.52. The stock has a market capitalization of $105.21 million, a P/E ratio of -29.46 and a beta of 1.35.
iCAD (NASDAQ:ICAD - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The technology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.04. The business had revenue of $4.87 million during the quarter, compared to the consensus estimate of $4.54 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in ICAD. Summit Trail Advisors LLC acquired a new position in iCAD during the 4th quarter worth approximately $214,000. Thompson Davis & CO. Inc. bought a new stake in shares of iCAD during the fourth quarter worth $31,000. First Eagle Investment Management LLC grew its stake in shares of iCAD by 6.1% during the fourth quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company's stock worth $1,311,000 after buying an additional 41,000 shares during the last quarter. PKS Advisory Services LLC acquired a new position in shares of iCAD during the fourth quarter worth $53,000. Finally, Geode Capital Management LLC lifted its stake in shares of iCAD by 6.6% in the 4th quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company's stock valued at $506,000 after acquiring an additional 17,059 shares during the last quarter. Institutional investors own 24.61% of the company's stock.
iCAD Company Profile
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Articles
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
